Palvella Therapeutics, Inc. (PVLA)
PVLA moved a median of +0.06% 30 minutes after news, and +1.50% by the close. How PVLA actually reacts to news — the realized, point-in-time move the market made, measured across 162 labeled events over the last three years with zero look-ahead.
PVLA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 159 |
| 30-min | +0.06% | 52% | 159 |
| 60-min | +0.07% | 51% | 160 |
| to close | +1.50% | 58% | 159 |
| Middle 50% of PVLA reactions | -1.33% to +1.83% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 162 |
Half of all Palvella Therapeutics, Inc. news events land between -1.33% and +1.83% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PVLA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 52 | -1.61% | 31% | +0.70% |
| Rating reiterations | 63 | +0.01% | 51% | +0.33% |
| Price-target raises | 18 | +0.39% | 67% | +0.38% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how PVLA ranks against every other measured name →
That’s how PVLA usually reacts — get an email when it moves on news →Email me when PVLA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PVLA's baseline. Nothing else.
Recent PVLA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Press release | GlobeNewswire | +0.14% | +1.23% | |
| Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Press release | GlobeNewswire | +1.97% | +2.77% | |
| Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences | Press release | GlobeNewswire | +1.20% | -0.53% | |
| Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Press release | GlobeNewswire | +0.17% | +3.14% | |
| Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference | Press release | GlobeNewswire | +0.76% | -0.22% | |
| Form 10-Q PALVELLA THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.97% | +12.34% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +4.97% | +12.34% | |
| Form S-8 PALVELLA THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | +0.76% | -0.22% | |
| Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +4.97% | +12.34% | |
| Palvella Therapeutics Chief Scientific Officer Jeff Martini, Ph.D. Selected to Present at Upcoming FDA Public Workshop on Drug Repurposing | Press release | GlobeNewswire | +0.00% | +3.94% | |
| Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026 | Press release | GlobeNewswire | +0.45% | +0.39% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Jul 14 | SEC filing · Form 8-K | SEC EDGAR | +0.03% | +3.54% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +0.39% | -0.86% | |
| Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors | Press release | GlobeNewswire | +0.39% | -0.86% | |
| Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations | Press release | GlobeNewswire | -0.04% | +4.67% | |
| FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations | Press release | GlobeNewswire | -0.49% | +3.08% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.85% | -5.88% | |
| ResVita Bio Appoints John D. Doux, M.D., M.B.A., to Board of Directors | Press release | PR Newswire | -0.59% | -1.72% | |
| Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations | Press release | GlobeNewswire | +2.10% | +7.13% | |
| Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 | Press release | GlobeNewswire | +0.00% | -5.37% | |
| Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043 | Press release | GlobeNewswire | +0.00% | -1.17% | |
| Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards | Press release | GlobeNewswire | -0.35% | +1.50% | |
| Form 8-K PALVELLA THERAPEUTICS, For: May 20 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | +1.50% | |
| Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformat | Press release | GlobeNewswire | -0.35% | +1.50% | |
| Form 8-K PALVELLA THERAPEUTICS, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | -2.40% | -2.21% | |
| Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology | Press release | GlobeNewswire | -2.40% | -2.21% | |
| Form 8-K PALVELLA THERAPEUTICS, For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -4.67% | |
| Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market | Press release | GlobeNewswire | -1.57% | -4.67% | |
| Form 10-Q PALVELLA THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -7.33% | -12.24% | |
| Form 8-K PALVELLA THERAPEUTICS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -7.33% | -12.24% | |
| Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -7.33% | -12.24% | |
| Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas | Press release | GlobeNewswire | +1.00% | +3.92% | |
| Form ARS PALVELLA THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.24% | -0.56% | |
| Form DEF 14A PALVELLA THERAPEUTICS, For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -0.24% | -0.56% | |
| Form DEFA14A PALVELLA THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | -0.24% | -0.56% | |
| Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026 | Press release | GlobeNewswire | +0.00% | +3.21% | |
| Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026 | Press release | GlobeNewswire | +0.64% | -0.52% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | +2.35% | |
| Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors | Press release | GlobeNewswire | +1.75% | +2.35% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | +3.47% | |
| Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales | Press release | GlobeNewswire | -0.98% | +2.94% | |
| Form 10-K PALVELLA THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -4.79% | +7.85% | |
| Form 8-K PALVELLA THERAPEUTICS, For: Mar 31 | SEC filing · Form 8-K | SEC EDGAR | -4.79% | +7.85% | |
| Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -4.79% | +7.85% | |
| Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations | Press release | GlobeNewswire | +0.35% | -1.45% | |
| Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting | Press release | GlobeNewswire | -0.08% | -3.43% | |
| Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 | Press release | GlobeNewswire | +0.96% | +1.07% | |
| Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services | Press release | GlobeNewswire | -0.28% | +2.38% | |
| Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin | Press release | GlobeNewswire | +2.86% | +1.59% | |
| Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations | Press release | GlobeNewswire | +0.00% | +4.58% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PVLA section they belong to.
Where else PVLA is measured.
PVLA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Palvella Therapeutics, Inc.'s median reaction calculated?
Every labeled PVLA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 162 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of PVLA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PVLA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.